机构：[1]Hebei Univ,Affiliated Hosp,Dept Radiat Oncol,Baoding 071000,Peoples R China河北大学附属医院[2]Hebei Univ,Affiliated Hosp,Dept Med Oncol,Baoding 071000,Peoples R China医疗肿瘤内科河北大学附属医院重点学科肿瘤内科
Background: A meta-analysis of randomized controlled trials was performed to determine the overall risk of noninfectious severe pneumonitis associated with mTOR inhibitors (mTORi) in cancer patients. Materials & methods: PubMed, EMBASE and oncology conference proceedings were searched for relevant studies. Results: A total of 8377 patients from 16 randomized controlled trials were included. The incidence of severe pneumonitis associated with mTORi was 1.7% (95% CI: 1.1-2.5%). The use of mTORi significantly increased the risk of severe pneumonitis compared with controls (odds ratio: 3.36; 95% CI: 2.20-5.12). The analysis was stratified for drug types, tumor types, controlled therapy and mTORi-based regimens, but no significant differences in odds ratios were observed. Conclusion: mTORi significantly increase the risk of severe pneumonitis in cancer patients.
第一作者机构：[1]Hebei Univ,Affiliated Hosp,Dept Radiat Oncol,Baoding 071000,Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Zhang Xi,Ran Yu-ge,Wang Kun-jie.Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials[J].FUTURE ONCOLOGY.2016,12(12):1529-1539.doi:10.2217/fon-2016-0020.
APA：
Zhang, Xi,Ran, Yu-ge&Wang, Kun-jie.(2016).Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials.FUTURE ONCOLOGY,12,(12)
MLA：
Zhang, Xi,et al."Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials".FUTURE ONCOLOGY 12..12(2016):1529-1539
